Lexicor Medical Technologies Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Lexicor Medical Technologies Inc.
FDA proposes class II for nonthermal shortwave therapy devices and updates regulations to reflect class II designation for neuropsychiatric assessment device. Meetings on manufacturing quality, clinical trials and medical countermeasures announced. More regulatory news.